Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 12/20 | 0.63 |
| ▸ | EDNRB | P24530 | 8/20 | 0.59 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30171185 | 1.00 | EDNRA (0.63) | EDNRAEDNRBBRD4 | |
| SCHEMBL30296336 | 0.86 | EDNRA (0.56) | EDNRAEDNRBBRD4 | |
| SCHEMBL5321684 | 0.86 | EDNRA (0.56) | EDNRAEDNRBBRD4 | |
| SCHEMBL30844573 | 0.86 | EDNRA (0.56) | EDNRAEDNRBBRD4 | |
| SCHEMBL5330400 | 0.86 | EDNRA (0.56) | EDNRAEDNRBBRD4 | |
| SCHEMBL26688897 | 0.83 | EDNRA (0.63) | EDNRAEDNRB | |
| SCHEMBL6557303 | 0.83 | EDNRA (0.48) | EDNRA | |
| SCHEMBL5324233 | 0.83 | EDNRA (0.56) | EDNRAEDNRBBRD4 | |
| SCHEMBL29281026 | 0.82 | EDNRA (0.46) | EDNRAEDNRB | |
| SCHEMBL29001495 | 0.81 | CCNT1 (0.43) | EDNRAEDNRBBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025094214-A1 | Process for the preparation of 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl) benzenesulfonamide and its intermediates thereof | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2025-05-08 | — | — | WO | claimed |
| WO-2025094214-A1 | Process for the preparation of 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl) benzenesulfonamide and its intermediates thereof | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2025-05-08 | — | — | WO | disclosed |
| US-20250051315-A1 | COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION | ALCHEMEDICINE, INC. (JP) | 2025-02-13 | — | — | US | disclosed |
| EP-4458826-A1 | COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION | Alchemedicine, Inc. (JP) | 2024-11-06 | — | — | EP | disclosed |
| CN-118284605-A | Compounds, angiotensin II type 1 receptor antagonists and pharmaceutical compositions | 亚克医药株式会社 | 2024-07-02 | — | — | CN | disclosed |
| WO-2023224963-A1 | DUAL-ACTING ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONISTS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023224963-A1 | DUAL-ACTING ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONISTS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023127853-A1 | COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION | 株式会社アークメディスン | 2023-07-06 | — | — | WO | disclosed |
| WO-2023127853-A1 | COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION | 株式会社アークメディスン | 2023-07-06 | — | — | WO | disclosed |
| WO-2023066348-A1 | DUAL ANTAGONIST AND USE THEREOF | 年衍药业（上海）有限公司 | 2023-04-27 | — | — | WO | disclosed |
| US-6638937-B2 | As antihypertensive agents; for therapy of disorders related to renal, glomerular and mesangial cell function; therapy of endotoxemia or endotoxin shock as well as hemorrhagic shock; useful in alleviation of pain associated cancer | BRISTOL-MYERS SQUIBB CO. | 2003-10-28 | — | — | US | disclosed |
| EP-1328523-A2 | METHODS FOR THE PREPARATION OF BIPHENYL ISOXAZOLE SULFONAMIDES | Bristol-Myers Squibb Company (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2002-10-03 | — | — | US | disclosed |
| US-20020132838-A1 | Methods for the preparation of biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-19 | — | — | US | disclosed |
| EP-1237888-A2 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2002032884-A2 | METHODS FOR THE PREPARATION OF BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
| WO-2001044239-A2 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB CO. (US) | 2001-06-21 | — | — | WO | disclosed |
| US-6043265-A | TREATING HYPERTENSION, PULMONARY HYPERTENSION, BENIGN PROSTATIC HYPERTROPHY, MIGRAINE, UROGENITAL DISORDERS, ENDOTOXEMIA, ISCHEMIA, ATHEROSCLEROSIS, RESTENOSIS, SUBARACHNOID HEMORRHAGE, CONGESTIVE HEART FAILURE | BRISTOL-MYERS SQUIBB CO. (US) | 2000-03-28 | — | — | US | disclosed |
| US-5846990-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB CO. (US) | 1998-12-08 | — | — | US | disclosed |
| US-5780473-A | Substituted biphenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | EDNRA 3/4885EDNRB 1/4885BRD4 158/4885 |
| US-20020132838-A1 | Methods for the preparation of biphenyl isoxazole sulfonamides | REN, STS, CYP4X1 | EDNRA 11/4885EDNRB 12/4885BRD4 149/4885 |
| US-20250051315-A1 | COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION | AGTR1, AGTR2, ADRB1 | EDNRA 154/4885EDNRB 216/4885BRD4 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.